Comparison · NCT01610414-711d1e03
GSK1437173A Group vs Placebo Group: Number of Subjects With Confirmed Herpes Zoster (HZ) Episode
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. GSK1437173A Group vs Placebo Group: Number of Subjects With Confirmed Herpes Zoster (HZ) Episode. Trial comparisons, record NCT01610414-711d1e03. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01610414-711d1e03
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0563 | 0.0429 | 0.0737 | wilson | |
| Risk in group 2 | 0.159 | 0.136 | 0.185 | wilson | |
| Risk difference, group 1 minus group 2 | -0.102 | -0.132 | -0.0735 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.355 | 0.26 | 0.485 | log | |
| Odds ratio, group 1 over group 2 | 0.317 | 0.225 | 0.446 | log | |
| Number needed to treat, for one fewer participant with the outcome on GSK1437173A Group than on Placebo Group | 9.77 | 7.6 | 13.6 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | GSK1437173A Group | Subjects received 2 doses of the candidate HZ vaccine GSK1437173A, administered intramuscularly (IM) in deltoid region of the non-dominant arm, according to a 0, 1-2-Months schedule. | 49 | 870 | OG000 |
| Group 2 | Placebo Group | Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of the non-dominant arm, according to a 0, 1-2-Months schedule. | 135 | 851 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Subjects With Confirmed Herpes Zoster (HZ) Episode
- Description
A suspected case of HZ was defined as (1) a new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations), or a vesicular rash suggestive of VZV infection regardless of the distribution, and no alternative diagnosis; or (2) a clinical presentation (symptoms and/or signs) and specific laboratory findings\* suggestive of VZV infection in the absence of characteristic HZ or VZV rash.~A suspected case of HZ was confirmed either: by Polymerase Chain Reaction (PCR) or by the HZ Ascertainment Committee (HZAC), consisting of physicians with HZ expertise.
- Time frame
- From Month 0 until the cut-off date for final analysis (median follow-up was of 21 months)
- Population
The analysis was performed on the modified Total Vaccinated Cohort, which excluded subjects from the Total Vaccinated Cohort analysis who were not administered with the second vaccination or who received vaccine doses/or replacement not on the same group or who developed a confirmed case of HZ prior to 1 month after the second vaccination.
Source ClinicalTrials.gov
Trial
- Title
- Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
- NCT number
- NCT01610414
- Phases
- PHASE3
- Conditions
- Herpes Zoster
- Interventions
- Herpes Zoster vaccine GSK1437173A, Placebo
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2018-01-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01610414?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01610414-711d1e03